Effect of Heparin on the Activation of Factor XI by Fibrin-bound Thrombin

Summary

Fibrin-bound thrombin is protected from inactivation by antithrombin III, while its coagulant potential is retained. In the presence of heparin, ternary complexes between thrombin, fibrin and heparin are formed. In these complexes the coagulant activity of thrombin is retained, whereas the anticoagulant activity of fibrin-bound heparin is neutralized. The limited effectiveness of heparin in the prevention of both venous thrombosis and coronary reocclusion is probably related to the protective effect of fibrin on the inactivation of thrombin by antithrombin III. Recently, it has been shown that factor XI can be activated by thrombin, resulting in the generation of additional thrombin via the intrinsic pathway. This additional thrombin is capable of stabilizing the clot by protecting it from fibrinolysis. We studied the effect of heparin on the activation of factor XI by fibrin-bound thrombin. First, we used fibrin monomers coupled to Sepharose to which thrombin and unfractionated heparin (UFH) were bound. Factor XI activation by thrombin was the same in the presence of fibrin-Sepharose or control-Sepha-rose. The addition of heparin (0.1 U/ml) resulted in a 91 and 15-fold enhancement in the presence of control-Sepharose and fibrin-Sepharose, respectively. Next, we added complexes of heparin, thrombin and fibrin monomer to factor XII and XI double-deficient plasma in the presence or absence of a reconstituting amount of factor XI. In the presence of factor XI, additional fibrin formation was observed indicating that factor XI activation by thrombin in complex with fibrin and heparin can take place in plasma. We then studied the effect of other heparin-like anticoagulants on the thrombin-mediated factor XI activation. UFH enhanced thrombin-mediated factor XI activation 68-fold, LMWH (low molecular weight heparin, Fragmin) 12-fold, danaparoid (Orgaran) 3-fold, while the pentasaccharide ORG 31540 did not result in an enhancement. Binding studies of these anticoagulants to fibrin-Sepharose showed that LMWH bound with approximately the same affinity as UFH, while danaparoid and the pentasaccharide did not bind to fibrin.

We conclude that fibrin-bound thrombin is capable of factor XI activation. Furthermore, heparin bound in a complex with fibrin can act as a cofactor for this activation. This factor XI activation capacity may play a role in the limited effectiveness of heparin. Provided that thrombin-mediated factor XI activation plays an important role in vivo, danaparoid and especially the pentasaccharide may be better anticoagulants than UFH and LMWH.

• References

• 1 Doolittle RF. Fibrinogen and fibrin. In: Haemostasis and Thrombosis, third edition, vol 1 Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD. (eds) Churchill Livingstone; Edinburgh, Great Britain: 1994: 491-513
• 2 Liu CY, Nossel HL, Kaplan KL. The binding of thrombin by fibrin. J Biol Chem 1979; 254: 10421-10425
• 3 Francis CW, Markham RE, Barlow GH, Florack TM, Dobrzynski DM, Marder VJ. Thrombin activity of fibrin thrombi and soluble plasmic derivatives. J Lab Clin Med 1983; 102: 220-230
• 4 Kumar R, Beguin S, Hemker HC. The influence of fibrinogen and fibrin on thrombin generation-evidence for feedback activation of the clotting system by clot bound thrombin. Thromb Haemost 1994; 72: 713-721
• 5 Hogg PJ, Jackson CM. Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy. Proc Natl Acad Sci USA 1989; 86: 3619-3623
• 6 Weitz JI, Hudoba M, Massel D, Maraganore J, Hirsh J. Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors. J Clin Invest 1990; 86: 385-391
• 7 Hogg PJ, Jackson CM. Heparin promotes the binding of thrombin to fibrin polymer. Quantitative characterization of a thrombin-fibrin polymer-hepa-rin ternary complex. J Biol Chem 1990; 265: 241-247
• 8 Hogg PJ, Jackson CM. Formation of a ternary complex between thrombin, fibrin monomer, and heparin influences the action of thrombin on its substrates. J Biol Chem 1990; 265: 248-255
• 9 Hotchkiss KA, Chesterman CN, Hogg PJ. Inhibition of heparin activity in plasma by soluble fibrin: evidence for ternary thrombin-fibrin-heparin complex formation. Blood 1994; 84: 498-503
• 10 Fuster V, Badimon L, Badimon JJ, Chesebro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes (Second of two parts). N Engl J Med 1992; 326: 310-318
• 11 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. J Biol Chem 1991; 266: 7353-7358
• 12 Gailani D, Broze GJ. Factor XI activation in a revised model of blood coagulation. Science 1991; 253: 909-912
• 13 Gailani D, Broze GJ. Effects of glycosaminoglycans on factor XI activation by thrombin. Blood Coagul Fibrinolysis 1993; 4: 15-20
• 14 Naito K, Fujikawa K. Activation of human blood coagulation factor XI independent of factor XII. Factor XI is activated by thrombin and factor XIa in the presence of negatively charged surfaces. Thromb Haemost 1991; 65: 144A
• 15 Scott CF, Colman RW. Fibrinogen blocks the autoactivation and thrombin-mediated activation of factor XI on dextran sulfate. Proc Natl Acad Sci USA 1992; 89: 11189-11193
• 16 von dem Borne PAK, Koppelman SJ, Bouma BN, Meijers JCM. Surface independent activation of factor XI by thrombin in the presence of high molecular weight kininogen. Thromb Haemost 1994; 72: 397-402
• 17 Gailani D, Broze GJ. Factor XH-independent activation of factor XI in plasma: Effect of sulfatides on tissue factor-induced coagulation. Blood 1993; 82: 813-819
• 18 von dem Borne PAK, Meijers JCM, Bouma BN. Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis. Blood 1995; 86: 3035-3042
• 19 Brunnee T, La Porta C, Reddigari SR, Salerno VM, Kaplan AP, Silverberg M. Activation of factor XI in plasma is dependent on factor XII. Blood 1993; 81: 580-586
• 20 Kerbiriou DM, Griffin JH. Human high molecular weight kininogen. Studies on structure-function relationships of proteolysis of the molecule occurring during contact activation in plasma. J Biol Chem 1979; 254: 12020-12027
• 21 Griffith MJ, Noyes CM, Church FC. Reactive site peptide structural similarity between heparin cofactor II and antithrombin III. J Biol Chem 1985; 260: 2218-2225
• 22 Miletich JP, Jackson CM, Majerus PW. Properties of the factor Xa binding site on platelets. J Biol Chem 1978; 253: 6908-6916
• 23 Van der Graaf F, Greengard JS, Bouma BN, Kerbiriou DM, Griffin JH. Isolation and functional characterization of the active light chain of activated human blood coagulation factor XI. J Biol Chem 1988; 258: 9669-9675
• 24 Meijers JCM, Tijburg PNM, Bouma BN. Inhibition of human blood coagulation factor Xa by α2-macroglobulin. Biochemistry 1987; 26: 5932-5937
• 25 Berliner LJ, Sugawara Y. Human α-thrombin binding to nonpolymerized fibrin-Sepharose: evidence for an anionic binding region. Biochemistry 1985; 24: 7005-7009
• 26 Heene DL, Matthias FR. Adsorption of fibrinogen derivatives on insolubilized fibrinogen and fibrinmonomer. Thromb Res 1973; 2: 137-154
• 27 Scott CF, Sinha D, Seaman FS, Walsh PN, Colman RW. Amidolytic assay of human factor XI in plasma: comparison with a coagulant assay and a new rapid radioimmunoassay. Blood 1984; 63: 42-50
• 28 Elgue G, Sanchez J, Egberg N, Olsson P. Coagulation inhibition capacities of low molecular mass and unfractionated heparin, as determined by thrombin generation. Thromb Res 1994; 75: 539-549
• 29 Pozdnjakova TM, Musjalkovskaja AA, Ugarova TP, Protvin DD, Kotsjuruba VN. On the properties of fibrin monomer prepared from fibrin clot with acetic acid. Thromb Res 1979; 16: 283-288
• 30 Meijers JCM. Regulation of the blood coagulation mechanism by plasma proteinase inhibitors. PhD Thesis State University of Utrecht; Utrecht, The Netherlands: 1988: 93-108
• 31 Baker WF, Bick RL. Deep vein thrombosis. Diagnosis and management. Med Clin North Am 1994; 78: 685-712
• 32 Bick RL. Disseminated intravascular coagulation. Objective criteria for diagnosis and management. Med Clin North Am 1994; 78: 511-543
• 33 Merlini PA, Cattaneo M, Spinola A, Ardissino D, Oltrona L, Belli C, Mannucci PM. Activation of the hemostatic system during thrombolytic therapy. Am J Cardiol 1993; 72: 59G-65G
• 34 Lopez-Femandez MF, Battle J, Soler R, Marini DiazM. Markers of haemostatic system activation in 80 patients with deep vein thrombosis submitted to fibrinolytic therapy. Fibrinolysis 1995; 9: 231-236
• 35 Shammas NW, Cunningham MJ, Pomerantz RM, Francis CW. Markers of hemostatic activation in affected coronary arteries during angioplasty. Thromb Haemost 1994; 72: 672-675
• 36 Ginsberg JS, Siragusa S, Douketis J, Johnston N, Moffat K, Stevens P, Brill-Edwards P, Panju A, Patel A. Evaluation of a soluble fibrin assay in patients with suspected deep vein thrombosis. Thromb Haemost 1995; 74: 833-836
• 37 Murakami T, Komiyama Y, Masuda M, Karakawa M, Iwasaka T, Taka-hashi H. Evaluation of factor XIa-oq-antitrypsin in plasma, a contact phase-activated coagulation factor-inhibitor complex, in patients with coronary artery disease. Arterioscler Thromb and Vase Biol 1995; 15: 1107-1113
• 38 Wuillemin WA. Activation and inactivation of factor XI in vitro and in vivo. PhD Thesis Free University of Amsterdam; Amsterdam, The Netherlands: 1996: 59-74
• 39 lino M, Takeya H, Takemitsu T, Nakagaki T, Gabazza EC, Suzuki K. Characterization of the binding of factor Xa to fibrinogen/fibrin derivatives and localization of the factor Xa binding site on fibrinogen. Eur J Biochem 1995; 232: 90-97